THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...
SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...
ZUG, Switzerland--(BUSINESS WIRE)--The joint venture between Biogen (NASDAQ:BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI® , an ...
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL ® ...
Enbrel (etanercept) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) to treat the following conditions: For each of these conditions, Enbrel is ...
SAN FRANCISCO, November 11, 2001– Data from a Phase 2 clinical study of ENBREL® (etanercept) in ankylosing spondylitis will be presented this week at the 65th Annual Scientific Meeting of the American ...
BEIJING--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first ...
Please provide your email address to receive an email when new articles are posted on . Etanercept and adalimumab are both impactful at improving the health of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback